Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
A

Aflibercept [Eylea]

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

No

Post-marketing information

Dear Healthcare Professional Letters

Subsidy Information and Financing Scheme

Medical Assistance Fund

Active ingredient: Aflibercept

General information

Subsidy Information and Financing Scheme

[MAF] Aflibercept (Eylea) Injection 2 mg/0.05 mL

  1. Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration.

  2. Treatment of adults with visual impairment due to diabetic macular oedema.

  3. Treatment of adults with visual impairment due to macular oedema secondary to retinal vein occlusion.

  4. Treatment of adults with visual impairment due to myopic choroidal neovascularisation.

[MAF] Aflibercept (Eylea) Injection, Prefilled Syringe 2 mg/0.05 mL

  1. Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration.

  2. Treatment of adults with visual impairment due to diabetic macular oedema.

  3. Treatment of adults with visual impairment due to macular oedema secondary to retinal vein occlusion.

  4. Treatment of adults with visual impairment due to myopic choroidal neovascularisation.

View legend

Drug Guidance for Subsidy

16/09/2025 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Aflibercept 2 mg/0.05 mL prefilled syringe and vial; and

  • Faricimab 6 mg/0.05 mL vial

for treating adults with visual impairment due to:

  • diabetic macular oedema; and

  • neovascular (wet) age-related macular degeneration.

Funding status

[R] Aflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2025.

[R] Faricimab 6 mg/0.05 mL vial is recommended for inclusion on the MAF for the abovementioned indications from 1 March 2024.

[NR] MAF assistance does not apply to other formulation(s) or strengths(s) of aflibercept and faricimab for treating diabetic macular oedema or neovascular age-related macular degeneration.

16/09/2025 Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion

The Ministry of Health’s Drug Advisory Committee has recommended aflibercept 2 mg/0.05 mL prefilled syringe and vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion.

The Ministry of Health’s Drug Advisory Committee has not recommended faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion, due to the unacceptable pricing proposal from the company.

Funding status

[R] Aflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.

[NR] MAF assistance does not apply to faricimab, and other formulation(s) or strengths(s) of aflibercept for the abovementioned indication.

View legend

Post Marketing Information

DHCPL 04/09/2014 Potential risk for medication error between ZALTRAP® (aflibercept, formulated for intravenous use) and EYLEA® (aflibercept, formulated for intravitreal use)

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Eylea Injection 2 mg/0.05 mL

  1. Alexandra Hospital

Eylea Injection, Prefilled Syringe 2 mg/0.05 mL

  1. Changi General Hospital

  2. Khoo Teck Puat Hospital

  3. Ng Teng Fong General Hospital

  4. National University Hospital

  5. Singapore National Eye Centre

  6. Tan Tock Seng Hospital

  7. Woodlands Health Campus

Eylea Injection, Solution 114.3 mg/mL

  1. Singapore National Eye Centre

  2. Tan Tock Seng Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information.

Intravitreous

* Clinical information is available for this product.

Back to top